Portfolio Update
MERRILL LYNCH GREATER EUROPE INVESTMENT TRUST plc
All information is at 31 January 2008 and unaudited.
Performance at month end with net income reinvested
One Three One Since Launch
Month Months Year (20Sep04)
Net asset value -12.2% -10.9% -0.9% 77.8%
Share price -11.4% -12.1% -0.5% 71.4%
FTSE World Europe ex UK -11.0% -10.2% 2.0% 70.1%
Sources: BlackRock and Datastream
At month end
Net asset value (capital only): 171.47p
Net asset value (including income): 171.40p*
Share price: 165.00p
*Includes net revenue of 0.07p
Discount to NAV (capital only): 3.8%
Discount to NAV (including income): 3.7%
Gearing: 5.4%
Net yield: 1.5%
Total assets: £208.7m
Ordinary shares in issue: 115,117,791
Benchmark
Sector Analysis Total Assets Index (%) Country Analysis Total Assets
(%) (%)
Financials 28.1 28.1 Germany 19.6
Health Care 10.7 6.9 France 15.4
Basic Materials 9.4 6.9 Switzerland 12.6
Utilities 9.3 8.7 Italy 10.6
Consumer Goods 8.2 13.8 Netherlands 7.2
Telecommunications 7.4 7.3 Spain 5.2
Oil & Gas 7.3 6.2 Finland 4.8
Technology 6.1 4.4 Russia 4.0
Industrials 5.9 12.6 Emerging Europe 4.0
Consumer Services 3.3 5.1 Turkey 3.7
Other Investments 4.1 - Belgium 2.2
Net current assets 0.2 - Greece 1.9
Austria 1.7
Ireland 1.6
Norway 1.4
Luxembourg 1.1
Poland 1.0
USA 1.0
Israel 0.7
UK 0.1
Net current assets 0.2
----- ----- -----
100.0 100.0 100.0
===== ===== =====
Ten Largest Equity Investments
Company Country of Risk
Banco Santander Spain
Bayer Germany
BlackRock Eurasian Frontiers Hedge Fund Emerging Europe
Electricite de France France
ENI Italy
Intesa Sanpaolo Italy
Nokia Finland
Novartis Switzerland
Roche Switzerland
Siemens Germany
Commenting on the markets, James Macmillan, representing the Investment Manager
noted:
European equity markets fell further in January with the FTSE World Europe ex
UK Index (NDR) posting a decline of -11.0% in Sterling terms. Investors showed
increasing concern that the US sub-prime crisis would negatively impact both
economic and corporate growth in Europe. The most significant piece of news was
the recognition by the US Federal Reserve and Government that the US economy
was in need of support. This was delivered by a 0.75% rate cut on 22 January in
an emergency session quickly followed by a further 0.50% cut on 31 January. The
European Central Bank failed to follow the Fed's lead and kept borrowing costs
at a six year high. Emerging Europe marginally outperformed the developed
European markets but the MSCI Emerging Europe still posted a decline of -10.7%
throughout January in Sterling terms as investors continued to be more cautious
about the de-coupling of emerging and developed economies.
The Company's NAV returned -12.2% underperforming the reference index. The
contribution from the Emerging Europe region was marginally negative, with the
benefit to the Company from its holding in the BlackRock Eurasian Frontiers
Hedge Fund and also successful stock selection in Israel failing to offset the
falls in Poland, Russia and Turkey. The Company's performance was adversely
impacted by positive gearing in a falling market.
During the month, the Company benefited from its exposure to defensive sectors,
in particular Pharmaceutical stocks, Teva Pharmaceutical Industries and
Roche, and Health Care stocks, Fresenius and Nobel Biocare, all delivering
strong performance. Within the Technology sector companies, Capgemini, Ness
Technologies and Nokia also boosted performance. Other positive contributors
included selective investments in Real Estate, Capital Goods and Technology.
The stocks which detracted from performance included our holdings in the
Materials sector, including chemical company Lanxess and, in the Energy sector,
Surgutneftegaz, as investors shied away from cyclical exposure. In addition,
stock selection in the Materials, Consumer Durables & Apparel and Food,
Beverage & Tobacco sectors was negative.
During the month, the Company reduced its holdings in the Chemical, Mining,
Utility and Pharmaceutical sectors. The sales proceeds were used to increase
holdings in Financials through the purchase of shares in Bank, BNP Paribas and
Insurance company, Zurich Financial Services Group and Telecoms, through
Telecom Italia.
The Company continues to have a bias towards financials, through Banks and Real
Estate, along with Health Care, Materials and Technology. Exposure to Emerging
Europe decreased during the month to finish at 13.4%, with the largest country
exposures being Turkey and Russia, along with the BlackRock Eurasian Frontiers
Hedge Fund which provides diversified exposure to the region. During the month
the Company slightly increased its net market exposure to 105.4%.
We remain positive on the prospects for European and Emerging European
equities. Global economic growth is clearly moderating in response to a weaker
US economy and the impact of higher credit costs, but central banks are
determined to ensure stability in the world financial system by applying the
appropriate monetary measures. At current prices, stocks carry attractive
valuations and, we believe, will begin to respond positively once markets look
forward to a resumption of stronger growth.
Latest information is available by typing www.blackrock.co.uk/its on the
internet, "BLRKINDEX" on Reuters, "BLRK" on Bloomberg or "8800" on Topic 3 (ICV
terminal).
25 February 2008